Brokerage firm Argus Research Upgrades its rating on AstraZeneca plc (ADR)(NYSE:AZN). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Argus Research was issued on Aug 29, 2016.
In a different note, Argus Research said it Initiates Coverage on AstraZeneca plc (ADR), according to a research note issued on Jul 12, 2016. The shares have been rated ‘Hold’ by the firm.
AstraZeneca plc (ADR) (AZN) shares turned negative on Thursdays trading session with the shares closing down -0.21 points or -0.64% at a volume of 65,30,974. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $32.69. The peak price level was also seen at $32.69 while the days lowest was $32.36. Finally the shares closed at $32.6. The 52-week high of the shares is $35.04 while the 52-week low is $26.97. According to the latest information available, the market cap of the company is $82,478 M.
AstraZeneca plc (ADR)(AZN) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.60B. Analysts had an estimated revenue of $5.68B. Earnings per share were $0.83. Analysts had estimated an EPS of $0.76.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).